Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey
- DOI
- 10.1097/cmr.0000000000000963
- Published
- 2024-03-28
- Container
- Melanoma Research
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/cmr.0000000000000963,
title = {Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey},
author = {Marie Fabre and Anouck Lamoureux and Laurent Meunier and Quentin Samaran and Candice Lesage and Céline Girard and Aurélie Du Thanh and Lionel Moulis and Olivier Dereure},
year = {2024},
journal = {Melanoma Research},
doi = {10.1097/cmr.0000000000000963},
url = {https://doi.org/10.1097/cmr.0000000000000963}
}RIS
TY - JOUR TI - Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey AU - Marie Fabre AU - Anouck Lamoureux AU - Laurent Meunier AU - Quentin Samaran AU - Candice Lesage AU - Céline Girard AU - Aurélie Du Thanh AU - Lionel Moulis AU - Olivier Dereure PY - 2024 JO - Melanoma Research DO - 10.1097/cmr.0000000000000963 UR - https://doi.org/10.1097/cmr.0000000000000963 ER -
APA
Fabre, M., Lamoureux, A., Meunier, L., Samaran, Q., Lesage, C., Girard, C., Thanh, A. D., Moulis, L., & Dereure, O. (2024). Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey. Melanoma Research. https://doi.org/10.1097/cmr.0000000000000963
Source records
- crossref · retrieved 2026-09-26T21:08:10.670Z